GlobeNewswire by notified

LIDDS Interim report January – September 2021

Share

JANUARY – SEPTEMBER 2021

  • Net sales amounted to MSEK 1.2 (0.0)
  • Operating expenses amounted to MSEK -29,5 (-19,8)
  • Profit/loss before and after tax amounted to MSEK -28.4 (-19.8)
  • Earnings per share amounted to SEK -0.90 (-0.76)
  • Cash flow from operating activities amounted to MSEK -32.7 (-17.3)
  • Equity amounted to MSEK 57.4 (55.2) and the debt/equity ratio was 90% (88%)

JULYSEPTEMBER 2021

  • Net sales amounted to MSEK 0.4 (0.0)
  • Operating expenses amounted to MSEK -8.2 (-6.6)
  • Profit/loss before and after tax amounted to MSEK -7.8 (-6.6)
  • Earnings per share amounted to SEK -0.26 (-0.23)
  • Cash flow from operating activities amounted to MSEK -9.2 (-5.2)
  • Equity amounted to MSEK 57.4 (55.2) and the debt/equity ratio was 90% (87%)

SIGNIFICANT EVENTS DURING THE THIRD QUARTER 2021

  • As part of the warrants-based incentive programme 2021/2024, a total of 146,000 warrants were subscribed to, by the CEO and key personnel at LIDDS. The remaining warrants are kept by LIDDS and will be offered to future key personnel in relation to employment.

SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

  • In October, the company announced that no further patients will be enrolled in its dose escalating Phase I study (NZ-DTX-001). The primary objective of the trial was to study safety of NanoZolid®-docetaxel in solid tumors.
  • The data collected in the trial demonstrates safety and tolerability, an active and local drug release of docetaxel over an extended period of time and signs of clinical effect in injected tumors. LIDDS plan to communicate topline results during Q4 2021.

CEO Statement

The autumn has made its entrance in Sweden and when reflecting on the progress we have made during the third quarter of this year I feel pride.

We are making good progress in our projects and in October we communicated the closing of our NZ-DTX-001 study. The scope of the study was to investigate safety and tolerability of the NanoZolid®-formulated cytotoxic drug docetaxel in patients with superficial tumours which also was accomplished. We are currently closing the study and preparing for next clinical step which will be communicated in 2021 together with the top-line results from the study. This program is clearly on strategy and a good example of the value LIDDS is generating given a safety profile of docetaxel that is severely limiting its application as a systemic drug. Local intratumorally administration will improve the safety and efficacy profile of docetaxel thus allowing targeting of new types of patients.

LIDDS has previously communicated the intent to initiate a clinical investigation of our first immunoncology drug which is a TLR9 agonist. I am personally very excited about this drug given the improved behaviour of it when formulated in our technology for local administration. Since I joined LIDDS we have performed preclinical studies where we have combined the TLR9 agonist with another substance and the data looks very promising. We even see signs of immune activity in non-treated tumours in our animal studies. Given the signs of abscopal effects when combining TLR9 we have decided to go into clinical development with a combination therapy rather than a monotherapy. This change means a delay in our clinical study but given the observed data we believe the combination will generate best value for all stakeholders. I can promise you that we will do our outmost to progress this program as promptly as possible. We are all excited and looking forward to the clinical data on this specific project!

The collaboration with Johnson & Johnson is progressing according to plan and we hope to be able to expand the cooperation in the future. In parallel, we are working on validating our phase III plans for Liproca Depot. As an important step, we submitted our phase III study protocol to the European Medicines Agency (EMA) for Scientific Advise (SA) on Sep 27.

We have set a direction for the company by defining what strategic areas to focus on to reach our key targets and our Vision 2026 which is to make “LIDDS the preferred solution and partner for elegant and optimal drug delivery - enabling better health!”. We are a drug delivery company and will remain so by investing in our technology and our projects, and in our people and our partnerships. The unique value of LIDDS is to deliver drugs that are both safer and more efficacious by administration of NanoZolid®-formulated depots delivering a controlled and sustained local release of drugs. We will present more details regarding our strategic focus early next year.

An important strategic focus area is to secure long-term financing of LIDDS to provide resources for a sustainable growth. We are currently continuing our preparations to make the move to Nasdaq Stockholm’s main list. This is part of the long-term perspective and something we work intensively on. As senior executives need to be in place in the company for at least a quarter before being listed on the main market this has taken longer time with the entrance of myself and of the new CFO. The ambition is to make the move in first half of 2022. The requirements that are added when listing on the main market represent an opportunity to increase the quality of our work, sharpen our value propositions and becoming a more mature company.

Given our vision, strategies and plans it is important to continue to grow the organization in an efficient and sustainable way. To be successful we need the best competences onboard. I am therefore very pleased that we have now the support of Johan Harmenberg. Johan has an excellent and relevant background as Chief Medical Officer in several oncology companies. With this background I am convinced that he will contribute very positively to our growth journey.

My colleagues and I are looking forward to the rest of 2021 and to 2022 where we expect to be able to present more details about our new strategic direction and about the progresses that we make in our projects. Progresses that ultimately will make a real difference to patients.

Thank you for your continued support of LIDDS!

Nina Herne, CEO

The interim report is available on the company’s website, go to https://liddspharma.com/investors/#financial-reports

For more information, please contact: 
Nina Herne, CEO, LIDDS +46 (0)70 714 74 57,  nina.herne@liddspharma.com

Jenni Björnulfson, CFO +46 (0)70 855 38 05, jenni.bjornulfson@liddspharma.com

LIDDS AB (PLC) is required to disclose this information in accordance with the EU Market Abuse Regulation. The information was submitted through the agency of the aforementioned contact, for publication on November 22, 2021 at 16.45 CET.

LIDDS AB (PLC) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and is superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens, and also has in-house development projects in the clinical as well as the preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

AMG Advanced Metallurgical Group N.V. Completes Issuance of $550 Million of Credit Facilities30.11.2021 22:00:00 CET | Press release

Amsterdam, 30November 2021--- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") is pleased to announce that it has entered into a new $350 million 7-year senior secured term loan B facility ("term loan") and a $200 million 5-year senior secured revolving credit facility ("revolver"). The total facility amount of $550 million replaces AMG’s existing credit facility and extends our term loan maturity from 2025 to 2028 and revolver maturity from 2023 to 2025. AMG will use the proceeds of the new term loan to refinance its existing credit facility. Further strengthening AMG’s commitment to Environmental, Social and Governance ("ESG"), we have embedded annual CO2 intensity reduction targets into the Revolving Credit Facility, making it a Sustainability Linked Loan. Moody's Investors Service ("Moody's") assigned a Ba3 rating to the new senior secured credit facility, affirmed our B2 corporate family rating and changed their outlook to positive from stable. S&P Global R

EPH European Property Holdings Limited (EPH) announces Third Quarter 2021 Financial Update30.11.2021 19:00:00 CET | Press release

30November 2021, Road Town, Tortola, BVI I Ad hoc announcement pursuant to Art. 53 LR In Q3 2021, there were no significant changes in the Company’s financial position and/or structure of its balance sheet in comparison to the published semi-annual report, given that fair value of investment properties was not revaluated as of 30 September 2021. In Q3 2021, the Company demonstrated stable performance compared to the last year. The rental properties continued generating sufficient cash to cover the Company’s operating expenses, service the debt and partially finance its investment program. The net rental income (NRI) increased from US$45.33 mln in the first 9 months of 2020 to US$ 49.38 mln for 9 months of 2021. Thereof, European properties acquired during 2020 generated a total NRI of US$ 7.48 mln (9 months of 2020: US$ 2.67 mln). The performance of the other European properties, as well as Russian properties remained almost unchanged as compared to the same period of 2020.During Q3 20

NEXTENSA NV/SA: SHARES – VOTING RIGHTS AND DENOMINATOR PUBLICATION IN COMPLIANCE WITH ART. 15 OF THE LAW OF 2 MAY 2007 (THE TRANSPARENCY ACT)30.11.2021 17:40:00 CET | Press release

NEXTENSA NV/SA: SHARES – VOTING RIGHTS AND DENOMINATOR PUBLICATION IN COMPLIANCE WITH ART. 15 OF THE LAW OF 2 MAY 2007 (THE TRANSPARENCY ACT) As previously announced1, the EGM of 19 July 2021 introduced the double voting right (loyalty voting right), in accordance with article 7:53 of the Code of Companies and Associations. This means, in accordance with article 28 of the articles of association, that double voting rights are granted to each fully paid-up share that has been continuously registered in the share register in the name of the same shareholder for at least two years. The other shares give right to one vote. The two-year period starts from the date of registration of the nominative shares in the share register. In compliance with article 15 of the aforementioned Transparency Act, every month the Company must publish, on its website and by means of a press release, the total capital, the changes to the total number of voting securities and the total number of voting rights, i

Change in the number of shares and votes in Sinch AB (publ)30.11.2021 17:35:00 CET | Press release

Stockholm, Sweden – November 30, 2021 – Sinch AB (publ), a global leader in cloud communications for mobile customer engagement, today announced that the number of shares and votes in Sinch AB (publ), registration number 556882-8908 (“Sinch”), amounts to 747,480,901 on November 30, 2021. The change in the number of shares and votes in November is a result of the issue of totally 1,317,537 new shares in connection with the closing of the acquisitions of MessageMedia and MessengerPeople, as previously communicated. For further information, please contact Ola Elmeland Investor Relations Director Mobile: +46 721 43 34 59 E-mail: investors@sinch.com Thomas Heath Chief Strategy Officer & Head of Investor Relations Mobile: +46 722 45 50 55 E-mail: investors@sinch.com About Sinch Sinch brings businesses and people closer with tools enabling personal engagement. Its leading cloud communications platform lets businesses reach every mobile phone on the planet, in seconds or less, through mobile m

Ändring av antalet aktier och röster i Sinch AB (publ)30.11.2021 17:35:00 CET | Pressemelding

Stockholm, Sverige – 30 november 2021 – Sinch AB (publ), en ledande global leverantör av molntjänster för kundinteraktion via mobilen, meddelade idag att antalet aktier och röster i Sinch AB (publ), org.nr 556882–8908 (”Sinch”), uppgår till 747 480 901 den 30 november 2021. Förändringen av antal aktier och röster under november har föranletts av att totalt 1 317 537 nya aktier har emitterats i samband med slutförandet av förvärven av MessageMedia och MessengerPeople, som tidigare har kommunicerats. För mer information, vänligen kontakta Ola Elmeland Investor Relations Director Mobile: +46 721 43 34 59 E-mail: investors@sinch.com Thomas Heath Chief Strategy Officer & Head of Investor Relations Mobile: +46 722 45 50 55 E-mail: investors@sinch.com Om Sinch Sinch utvecklar digitala verktyg som möjliggör en personlig interaktion mellan företag och individer. Med Sinch molnbaserade kommunikationsplattform kan företag nå världens alla mobiltelefoner – inom en eller ett par sekunder – via medd

GivingTuesday: NOVA Chemicals Expands Total COVID-19 Relief to US$1.25M with Additional Gifts30.11.2021 16:40:00 CET | Press release

Programs supporting mental health, food security, and overall community resiliency receive funding through corporate giving campaign Calgary, Alberta, Canada , Nov. 30, 2021 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation, 1000 Seventh Avenue S.W., Calgary, Alberta, Canada T2P 5L5 www.novachemicals.com | 403.750.3600 tel | 403.269.7410 fax NOVA Chemicals Corporation (“NOVA Chemicals”) today announced an additional US$600,000 commitment in COVID-19-related supports across our operational regions, bringing the total amount given for pandemic relief to US$1.25M, as part of efforts to meaningfully give back to our neighbors and their communities. “While we continue to see positive momentum toward a world with higher vaccination rates and fewer restrictions, the impacts felt by the pandemic will unfortunately have lasting effects,” said Mona Jasinski, SVP HR and Communications, NOVA Chemicals. “I am proud of NOVA’s commitment to ensuring there is food on the table for tens of thousands of pe

KICKS CHOSES WESTPAY AS PROVIDER OF PAYMENT SOLUTIONS30.11.2021 16:40:00 CET | Press release

Westpay has today signed an agreement with Kicks regarding payment solutions in Sweden, Norway, and Finland. The solution enables card payments as well as Swish, Vipps, Mobile Pay, and other alternative payment methods. The value of the initial order amounts close to SEK 4 million during the coming three years. - Kicks is a solid and well-known brand in the Nordics. The customer experience is a key element in their success. Westpay and our solutions enable all the features and solutions they need to level up their overall offering. They made an accurate and relevant assessment and knew that their payment solution was required to support them in their ongoing business today as well as tomorrow. Now, they have a future-proof solution that they can rely on in their future journey, says Hans Edin, CCO at Westpay. KICKS is the Nordic region's leading beauty chain and offers a holistic concept in makeup, fragrance, skin care and hair care. With experts in 250 stores in Sweden, Norway and Fin